LY262691 is a selective CCKB antagonist, which decreases midbrain dopamine unit activity.
Uses
LY262691 is a selective CCK-B antagonist with antipsychotic properties. LY262691 decreases the number of spontaneously active A9 and A10 dopamine cells and can be utilized in antipsychotic research[1].
References
[1] Rasmussen K, et al. Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity. Eur J Pharmacol. 1991 Dec 10;209(1-2):135-8. DOI:10.1016/0014-2999(91)90025-l
